Reference
Ai, X., Guo, X., Wang, J., Stancu, A.
L., Joslin, P. M. N., Zhang, D., & Zhu, S. (2018). Targeted therapies
for advanced non-small cell lung cancer. Oncotarget, 9 (101),
37589-37607. doi:10.18632/oncotarget.26428
Alfaro, C. L. (2001). Emerging role of
drug interaction studies in drug development: the good, the bad, and the
unknown. Psychopharmacol Bull, 35 (4), 80-93.
Androutsopoulos, V. P., Spyrou, I.,
Ploumidis, A., Papalampros, A. E., Kyriakakis, M., Delakas, D., . . .
Tsatsakis, A. M. (2013). Expression profile of CYP1A1 and CYP1B1 enzymes
in colon and bladder tumors. PLoS One, 8 (12), e82487.
doi:10.1371/journal.pone.0082487
Curtis, M. J., Alexander, S., Cirino,
G., Docherty, J. R., George, C. H., Giembycz, M. A., . . . Ahluwalia, A.
(2018). Experimental design and analysis and their reporting II: updated
and simplified guidance for authors and peer reviewers. Br J
Pharmacol, 175 (7), 987-993. doi:10.1111/bph.14153
Das, M., Padda, S. K., Frymoyer, A.,
Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib
and erlotinib in patients with metastatic non-small cell lung cancer: A
drug-drug interaction. Lung Cancer, 89 (3), 280-286.
doi:10.1016/j.lungcan.2015.06.011
Filppula, A. M., Neuvonen, P. J., &
Backman, J. T. (2014). In vitro assessment of time-dependent inhibitory
effects on CYP2C8 and CYP3A activity by fourteen protein kinase
inhibitors. Drug Metab Dispos, 42 (7), 1202-1209.
doi:10.1124/dmd.114.057695
Galetti, M., Petronini, P. G.,
Fumarola, C., Cretella, D., La Monica, S., Bonelli, M., . . . Alfieri,
R. R. (2015a). Effect of ABCG2/BCRP Expression on Efflux and Uptake of
Gefitinib in NSCLC Cell Lines. PLoS One, 10 (11), e0141795.
doi:10.1371/journal.pone.0141795
Galetti, M., Petronini, P. G.,
Fumarola, C., Cretella, D., La Monica, S., Bonelli, M., . . . Alfieri,
R. R. (2015b). Effect of ABCG2/BCRP Expression on Efflux and Uptake of
Gefitinib in NSCLC Cell Lines. Plos One, 10 (11).
Huang, L., & Fu, L. (2015).
Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta
Pharm Sin B, 5 (5), 390-401. doi:10.1016/j.apsb.2015.07.001
Kazandjian, D., Blumenthal, G. M.,
Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016). FDA Approval of
Gefitinib for the Treatment of Patients with Metastatic EGFR
Mutation-Positive Non-Small Cell Lung Cancer. Clinical Cancer
Research, 22 (6), 1307-1312.
Kitazaki, T., Oka, M., Nakamura, Y.,
Tsurutani, J., Doi, S., Yasunaga, M., . . . Kohno, S. (2005). Gefitinib,
an EGFR tyrosine kinase inhibitor, directly inhibits the function of
P-glycoprotein in multidrug resistant cancer cells. Lung Cancer,
49 (3), 337-343. doi:10.1016/j.lungcan.2005.03.035
Li, X., Zhong, K., Guo, Z., Zhong,
D., & Chen, X. (2015). Fasiglifam (TAK-875) Inhibits Hepatobiliary
Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver
Injury. Drug Metab Dispos, 43 (11), 1751-1759.
doi:10.1124/dmd.115.064121
Lu, J., Shang, X., Zhong, W., Xu, Y.,
Shi, R., & Wang, X. (2020). New insights of CYP1A in endogenous
metabolism: a focus on single nucleotide polymorphisms and diseases.Acta Pharm Sin B, 10 (1), 91-104. doi:10.1016/j.apsb.2019.11.016
Malapelle, U., Muscarella, L. A.,
Pisapia, P., & Rossi, A. (2020). Targeting emerging molecular
alterations in the treatment of non-small cell lung cancer: current
challenges and the way forward. Expert Opin Investig Drugs , 1-10.
doi:10.1080/13543784.2020.1732922
Oyama, T., Sugio, K., Isse, T.,
Matsumoto, A., Nose, N., Uramoto, H., . . . Kawamoto, T. (2008).
Expression of cytochrome P450 in non-small cell lung cancer. Front
Biosci, 13 , 5787-5793.
Rahman, A. F., Korashy, H. M., &
Kassem, M. G. (2014). Gefitinib. Profiles Drug Subst Excip Relat
Methodol, 39 , 239-264. doi:10.1016/B978-0-12-800173-8.00005-2
Ranson, M., & Wardell, S. (2004).
Gefitinib, a novel, orally administered agent for the treatment of
cancer. J Clin Pharm Ther, 29 (2), 95-103.
doi:10.1111/j.1365-2710.2004.00543.x
Wahid, M., Mahjabeen, I., Baig, R.
M., & Kayani, M. A. (2013). Expression of CYP1A1 and GSTP1 in human
brain tumor tissues in Pakistan. Asian Pac J Cancer Prev, 14 (12),
7187-7191. doi:10.7314/apjcp.2013.14.12.7187
Wang., Y., & Jin, R. (2018). The
research progress of c-Met inhibitors in clinical trials. Cancer
Cell Research, 20 , 524-528.
Xi, N., Zhang, Y. J., Wang, Z. H.,
Wu, Y. J., & Wang, T. J. (2014). CT053PTSA, a novel c-MET and VEGFR2
inhibitor, potently suppresses angiogenesis and tumor growth.Cancer Research, 74 (19). doi:10.1158/1538-7445.Am2014-1755
Xia, P., Cao, J., Lv, X., Wang, L.,
Lv, W., & Hu, J. (2018). Combination therapy of apatinib with icotinib
for primary acquired icotinib resistance in patients with advanced
pulmonary adenocarcinoma with EGFR mutation. Thorac Cancer, 9 (5),
656-661. doi:10.1111/1759-7714.12624
Zheng, W., Zhao, Y., Luo, Q., Zhang,
Y., Wu, K., & Wang, F. Y. (2017). Multi-Targeted Anticancer Agents.Current Topics in Medicinal Chemistry, 17 (28), 3084-3098.